Accelerate Diagnostics (NASDAQ:AXDX) Raised to “Hold” at StockNews.com

Accelerate Diagnostics (NASDAQ:AXDX) was upgraded by StockNews.com from a “sell” rating to a “hold” rating in a report released on Thursday.

Accelerate Diagnostics Trading Down 1.1 %

NASDAQ AXDX opened at $1.85 on Thursday. The business has a fifty day simple moving average of $1.78 and a 200 day simple moving average of $1.47. Accelerate Diagnostics has a 12 month low of $0.73 and a 12 month high of $5.78. The firm has a market capitalization of $46.32 million, a P/E ratio of -0.65 and a beta of 0.59.

Institutional Investors Weigh In On Accelerate Diagnostics

A hedge fund recently raised its stake in Accelerate Diagnostics stock. Griffin Asset Management Inc. increased its stake in Accelerate Diagnostics, Inc. (NASDAQ:AXDX) by 1.9% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 1,380,654 shares of the medical research company’s stock after purchasing an additional 26,400 shares during the quarter. Griffin Asset Management Inc. owned approximately 6.26% of Accelerate Diagnostics worth $1,615,000 at the end of the most recent quarter. 17.14% of the stock is owned by hedge funds and other institutional investors.

Accelerate Diagnostics Company Profile

Accelerate Diagnostics, Inc, an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms.